Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma

Clinical Therapeutics

Volumn 22, Issue 12, 2000, Pages 1562-1574

  Stempel, David A ^a   Stanford, Richard H ^b   Thwaites, Robert M A ^c   Price, Martin J ^c  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Budesonide; Cost efficacy; Fluticasone propionate

Indexed keywords

BUDESONIDE; FLUTICASONE PROPIONATE; SALBUTAMOL;

ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OUTCOMES RESEARCH; PEAK EXPIRATORY FLOW; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

EID: 0034531440     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)83054-4     Document Type: Article

References (37)

1. Current estimates from the National Health Interview Survey, 1994
2. The cost of asthma: Can it be reduced?
3. Use of a pharmacy and medical claims database to document cost centers for 1993 annual asthma expenditures
4. An economic evaluation of asthma in the United States
5. A national estimate of the economic costs of asthma
6. Mucosal inflammation in asthma
7. Inflammation and cell-cell interactions in airway hyperresponsiveness
8. Asthma and inflammation
9. Mediators of immediate hypersensitivity
10. Neuropeptides and asthma
11. Asthma and mast cell activation
12. Leukotrienes and airway responses
13. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma
14. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study
15. The British guidelines on asthma management
16. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma
17. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 μg/day with inhaled beclomethasone dipropionate 400 μg/day in mild and moderate asthma
18. Clinical experience with fluticasone propionate in asthma: A meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less
19. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children
20. Fluticasone propionate and budesonide in adult asthmatics: A comparison using dry-powder inhaler devices
21. A multicentre study to compare the efficacy and safety of inhaled fluticasone propionate and budesonide via metered dose inhalers in adults with mildto-moderate asthma
22. A comparison of fluticasone propionate 100 μg twice daily with 200 μg budesonide twice daily via their respective powder devices in the treatment of mild asthma
23. Fluticasone propionate Diskus 250 μg bd compared with budesonide Turbohaler 600 μg bd in adult asthmatics
24. Ease of handling and clinical efficacy of fluticasone propionate Accuhaler/Diskus inhaler compared with the budesonide Turbohaler inhaler in paediatric patients
25. A blinded comparison of fluticasone propionate with budesonide in adult patients with moderate-to-severe asthma
26. Efficacy of fluticasone propionate (0.5 mg daily) via MDI and budesonide (1.2 mg daily) via Turbohaler in the treatment of steroidnaive asthmatics
27. The episode-free day as a composite measure of effectiveness. An illustrative economic evaluation of formoterol versus salbutamol in asthma therapy
28. Charge what you will...reimbursements are shrinking
29. The cost of asthma in the emergency department and hospital
30. National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care
31. A comparison of the cost-effectiveness of alternative prophylactic therapies in the treatment of adult asthma
32. Cost and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease
33. Cost-effectiveness of fluticasone propionate and budesonide in patients with moderate asthma
34. A comparison of the cost-effectiveness of budesonide and fluticasone propionate drypowder devices in the management of asthma